MedTech Dive74d agoneutral
Insulet launches Omnipod 5 in SpainA high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain an attractive market for Insulet.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
65last 24h
976last 7d
109● bullish (7d)
124● bearish (7d)
212publishers
Insider Monkey103d agoneutral
Insulet (PODD) Enhances Omnipod 5 System with New Target Glucose OptionInsulet Corporation (NASDAQ:PODD) is one of the oversold stocks to buy right now. On June 3, Insulet launched significant enhancements to its Omnipod 5 Automated Insulin Delivery/AID System in the US, featuring a new 100 mg/dL Target Glucose option. This update allows for greater personalization and improved glycemic control, enabling users to increase their time […]
Simply Wall St.106d agobullish
Is Omnipod 5’s Algorithm and Libre 3 Plus Upgrade Altering The Investment Case For Insulet (PODD)?In early June 2026, Insulet began rolling out FDA-cleared algorithm enhancements to its Omnipod 5 Automated Insulin Delivery System in the U.S., adding a 100 mg/dL target option and new compatibility with Abbott’s Libre 3 Plus sensor via over-the-air updates and newly shipped Pods. This combination of tighter glucose personalization, improved automated mode performance, and broader sensor choice strengthens Omnipod 5’s appeal for both patients and clinicians even as the company manages...